393 related articles for article (PubMed ID: 17208435)
21. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
22. Novel C-5 aminomethyl pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Mastalerz H; Chang M; Gavai A; Johnson W; Langley D; Lee FY; Marathe P; Mathur A; Oppenheimer S; Tarrant J; Tokarski JS; Vite GD; Vyas DM; Wong H; Wong TW; Zhang H; Zhang G
Bioorg Med Chem Lett; 2007 May; 17(10):2828-33. PubMed ID: 17368025
[TBL] [Abstract][Full Text] [Related]
23. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
[TBL] [Abstract][Full Text] [Related]
24. Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer.
Baron AT; Wilken JA; Haggstrom DE; Goodrich ST; Maihle NJ
IDrugs; 2009 May; 12(5):302-8. PubMed ID: 19431095
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ; Sandler AB
Cancer Treat Rev; 2004 Feb; 30(1):1-17. PubMed ID: 14766123
[TBL] [Abstract][Full Text] [Related]
26. The development of HKI-272 and related compounds for the treatment of cancer.
Wissner A; Mansour TS
Arch Pharm (Weinheim); 2008 Aug; 341(8):465-77. PubMed ID: 18493974
[TBL] [Abstract][Full Text] [Related]
27. Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Norris D; Mastalerz H; Chen P; Goyal B; Zhao Y; Kim SH; Vite GD; Lee FY; Zhang H; Oppenheimer S; Tokarski JS; Wong TW; Gavai AV
Bioorg Med Chem Lett; 2011 Jan; 21(2):781-5. PubMed ID: 21177105
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
30. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
31. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
32. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of HER-2 inhibitors.
Rabindran SK
Cancer Lett; 2005 Sep; 227(1):9-23. PubMed ID: 16051028
[TBL] [Abstract][Full Text] [Related]
34. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Bijman MN; van Berkel MP; Kok M; Janmaat ML; Boven E
Anticancer Drugs; 2009 Jul; 20(6):450-60. PubMed ID: 19369859
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y; Yarden Y
Semin Cancer Biol; 2004 Aug; 14(4):262-70. PubMed ID: 15219619
[TBL] [Abstract][Full Text] [Related]
37. ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
Friedländer E; Barok M; Szöllosi J; Vereb G
Immunol Lett; 2008 Mar; 116(2):126-40. PubMed ID: 18201769
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
Nelson MH; Dolder CR
Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
[TBL] [Abstract][Full Text] [Related]
39. Are HER1/EGFR interactions with ligand free HER2 related to the effects of HER1-targeted drugs?
Kurbel S
Med Hypotheses; 2006; 67(6):1355-7. PubMed ID: 16890381
[TBL] [Abstract][Full Text] [Related]
40. New dual inhibitors of EGFR and HER2 protein tyrosine kinases.
Fink BE; Vite GD; Mastalerz H; Kadow JF; Kim SH; Leavitt KJ; Du K; Crews D; Mitt T; Wong TW; Hunt JT; Vyas DM; Tokarski JS
Bioorg Med Chem Lett; 2005 Nov; 15(21):4774-9. PubMed ID: 16111887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
